Amitifadine
Alternative Names: Amitifadine hydrochloride; DOV-21947; EB-1010Latest Information Update: 28 Apr 2024
At a glance
- Originator DOV Pharmaceutical
- Developer Ethismos Research; Euthymics Bioscience
- Class Antidepressants; Chlorobenzenes; Pyrrolidines; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Alcoholism; Depressive disorders; Opioid-related disorders; Pain; Smoking withdrawal; Substance-related disorders
- Discontinued Major depressive disorder; Obesity
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for preclinical development in Depressive disorders in USA (PO)
- 28 Apr 2024 No recent reports of development identified for preclinical development in Opioid-related-disorders in USA (PO)
- 28 Apr 2024 No recent reports of development identified for preclinical development in Pain in USA (PO)